mrjСовременная ревматологияModern Rheumatology Journal1996-70122310-158XIMA-PRESS, LLC10.14412/1996-7012-2021-4-87-93mrj-1176Research ArticleКЛИНИЧЕСКИЕ НАБЛЮДЕНИЯCLINICAL OBSERVATIONSТрудности ведения больных системной красной волчанкой и антифосфолипидным синдромом в сочетании с меланомой и инфильтративным туберкулезом (клинические наблюдения)Difficulties in management of patients with systemic lupus erythematosus and antiphospholipid syndrome in combination with melanoma and infiltrative tuberculosis (clinical observations)https://orcid.org/0000-0003-1318-1894ШумиловаА. А.ShumilovaA. A.

Анастасия Александровна Шумилова

115522, Москва, Каширское шоссе, 34А

Anastasia Aleksandrovna Shumilova

Kashirskoye shosse, 34A, Moscow 115522

aastudennikova@mail.ruhttps://orcid.org/0000-0003-3552-2522РешетнякТ. М.ReshetnyakT. M.

кафедра ревматологии

115522, Москва, Каширское шоссе, 34А125993, Москва, ул. Баррикадная, 2/1, стр. 1

Department of Rheumatology

Kashirskoye shosse, 34A, Moscow 1155222/1, Barrikadnaya St., Build. 1, Moscow 125993

https://orcid.org/0000-0001-5217-4932ЧельдиеваФ. А.CheldievaF. A.

кафедра ревматологии

115522, Москва, Каширское шоссе, 34А125993, Москва, ул. Баррикадная, 2/1, стр. 1

Department of Rheumatology

Kashirskoye shosse, 34A, Moscow 1155222/1, Barrikadnaya St., Build. 1, Moscow 125993

https://orcid.org/0000-0002-6068-3080ЛилаА. М.LilaA. M.

кафедра ревматологии

115522, Москва, Каширское шоссе, 34А125993, Москва, ул. Баррикадная, 2/1, стр. 1

Department of Rheumatology

Kashirskoye shosse, 34A, Moscow 1155222/1, Barrikadnaya St., Build. 1, Moscow 125993

ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»РоссияV.A. Nasonova Research Institute of RheumatologyRussian FederationФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»; ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования»РоссияV.A. Nasonova Research Institute of Rheumatology; Russian Medical Academy of Continuing Professional EducationRussian FederationФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»РоссияV.A. Nasonova Research Institute of Rheumatology; Russian Medical Academy of Continuing Professional EducationRussian Federation2021140820211548793Copyright © Шумилова А.А., Решетняк Т.М., Чельдиева Ф.А., Лила А.М., 20212021Шумилова А.А., Решетняк Т.М., Чельдиева Ф.А., Лила А.М.Shumilova A.A., Reshetnyak T.M., Cheldieva F.A., Lila A.M.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://mrj.ima-press.net/mrj/article/view/1176

Представлено два клинических наблюдения: в одном из них имелись антифосфолипидный синдромом (АФС) и меланома, в другом – системная красная волчанка (СКВ) и АФС, меланома, инфильтративный туберкулез и Herpes zoster. Ведение больных СКВ в сочетании с АФС – непростая задача. Инфекции и злокачественные новообразования наряду с поражением почек и сердечно-сосудистыми заболеваниями являются значимой причиной смерти в этой когорте больных. Продолжает обсуждаться роль антител к фосфолипидам в возникновении малигнизации. Сочетание ревматических заболеваний с онкологической или инфекционной патологией затрудняет терапию, ограничивая возможность применения препаратов, регламентированных клиническими рекомендациями.

We present two clinical cases: the first patient had combination of antiphospholipid syndrome (APS) and melanoma, and the second – systemic lupus erythematosus (SLE) and APS, melanoma, infiltrative tuberculosis and Herpes zoster. Managing patients with SLE combined with APS is really challenging. Infections and malignant neoplasms, along with kidney damage and cardiovascular diseases, are a significant cause of death in this cohort of patients. The role of antibodies to phospholipids in the onset of malignancy is still under discussion. The combination of rheumatic diseases with oncological or infectious pathology complicates therapy, limiting the use of drugs, recommended by clinical guidelines.

антифосфолипидный синдромсистемная красная волчанкамеланоматуберкулез легкихклинические наблюденияantiphospholipid syndromesystemic lupus erythematosusmelanomapulmonary tuberculosisclinical observationsИсследование выполнено в рамках темы «Разработка методов персонифицированной терапии ревматических заболеваний с коморбидной патологией» (АААА-А19-119021190151-3, 0514-2019-0020).The investigation has been conducted within scientific topic «Development of methods for personalized therapy of rheumatic diseases with comorbid pathology» (№АААА-А19-119021190151-3, 0514-2019-0020).ReferencesНасонов ЕЛ, редактор. Российские клинические рекомендации. Ревматология. Москва: ГЭОТАР-Медиа; 2017. 464 с.Nasonov EL, editor. Rossiiskie klinicheskie rekomendatsii. Revmatologiya [Russian clinical guidelines. Rheumatology]. Moscow: GEOTAR-Media; 2017. 464 p..D'Cruz DP, Mellor-Pita S, Joven B, et al. Transverse myelitis as the first manifestation of systemic lupus erythematosus or lupus-like disease: good functional outcome and relevance of antiphospholipid antibodies. J Rheumatol. 2004 Feb;31(2):280-5.D'Cruz DP, Mellor-Pita S, Joven B, et al. Transverse myelitis as the first manifestation of systemic lupus erythematosus or lupus-like disease: good functional outcome and relevance of antiphospholipid antibodies. J Rheumatol. 2004 Feb;31(2):280-5.Насонов ЕЛ. Антифосфолипидный синдром. Монография. Москва: Литтера; 2004. 36 с.Nasonov EL. Antifosfolipidnyi sindrom. Monografiya [Antiphospholipid syndrome. Monograph]. Moscow: Littera; 2004. 36 p.Решетняк ТМ. Антифосфолипидный синдром: диагностика и клинические проявления (лекция). Научно-практическая ревматология. 2014;52(1):56-71.Reshetnyak TM. Antiphospholipid syndrome: diagnosis and clinical manifestations (lecture). Nauchno-prakticheskaya revmatologiya. 2014;52(1):56-71. (In Russ.).Ocampo-Piraquive V, Nieto-Aristizabal I, Canas CA, Tobon GJ. Mortality in systemic lupus erythematosus: causes, predictors and interventions. Expert Rev Clin Immunol. 2018 Dec;14(12):1043-53. doi: 10.1080/1744666X.2018.1538789.Ocampo-Piraquive V, Nieto-Aristizabal I, Canas CA, Tobon GJ. Mortality in systemic lupus erythematosus: causes, predictors and interventions. Expert Rev Clin Immunol. 2018 Dec;14(12):1043-53. doi: 10.1080/1744666X.2018.1538789.Rodriguez-Pinto I, Moitinho M, Santacreu I, et al. Catastrophic antiphospholipid syndrome (CAPS): Descriptive analysis of 500 patients from the International CAPS Registry. Autoimmun Rev. 2016 Dec;15(12): 1120-4. doi: 10.1016/j.autrev.2016.09.010. Epub 2016 Sep 15.Rodriguez-Pinto I, Moitinho M, Santacreu I, et al. Catastrophic antiphospholipid syndrome (CAPS): Descriptive analysis of 500 patients from the International CAPS Registry. Autoimmun Rev. 2016 Dec;15(12): 1120-4. doi: 10.1016/j.autrev.2016.09.010. Epub 2016 Sep 15.Pettersson T, Pukkala E, Teppo L, Friman C. Increased risk of cancer in patients with systemic lupus erythematosus. Ann Rheum Dis. 1992 Apr;51(4):437-9. doi: 10.1136/ard.51.4.437.Pettersson T, Pukkala E, Teppo L, Friman C. Increased risk of cancer in patients with systemic lupus erythematosus. Ann Rheum Dis. 1992 Apr;51(4):437-9. doi: 10.1136/ard.51.4.437.Islam MA. Antiphospholipid antibodies and antiphospholipid syndrome in cancer: Uninvited guests in troubled times. Semin Cancer Biol. 2020 Aug;64:108-13. doi: 10.1016/j.semcancer.2019.07.019. Epub 2019 Jul 24.Islam MA. Antiphospholipid antibodies and antiphospholipid syndrome in cancer: Uninvited guests in troubled times. Semin Cancer Biol. 2020 Aug;64:108-13. doi: 10.1016/j.semcancer.2019.07.019. Epub 2019 Jul 24.Mendoza-Pinto C, Garcia-Carrasco M, Cervera R. Role of Infectious Diseases in the Antiphospholipid Syndrome (Including Its Catastrophic Variant). Curr Rheumatol Rep. 2018 Aug 20;20(10):62. doi: 10.1007/s11926-018-0773-x.Mendoza-Pinto C, Garcia-Carrasco M, Cervera R. Role of Infectious Diseases in the Antiphospholipid Syndrome (Including Its Catastrophic Variant). Curr Rheumatol Rep. 2018 Aug 20;20(10):62. doi: 10.1007/s11926-018-0773-x.Rastrelli M, Tropea S, Rossi CR, Alaibac M. Melanoma: epidemiology, risk factors, pathogenesis, diagnosis and classification. In Vivo. Nov-Dec 2014;28(6):1005-11.Rastrelli M, Tropea S, Rossi CR, Alaibac M. Melanoma: epidemiology, risk factors, pathogenesis, diagnosis and classification. In Vivo. Nov-Dec 2014;28(6):1005-11.Rigel DS. Epidemiology of melanoma. Semin Cutan Med Surg. 2010 Dec;29(4): 204-9. doi: 10.1016/j.sder.2010.10.005.Rigel DS. Epidemiology of melanoma. Semin Cutan Med Surg. 2010 Dec;29(4): 204-9. doi: 10.1016/j.sder.2010.10.005.Gandini S, Sera F, Cattaruzza MS, et al. Meta-analysis of risk factors for cutaneous melanoma: II. Sun exposure. Eur J Cancer. 2005 Jan;41(1):45-60. doi: 10.1016/j.ejca.2004.10.016.Gandini S, Sera F, Cattaruzza MS, et al. Meta-analysis of risk factors for cutaneous melanoma: II. Sun exposure. Eur J Cancer. 2005 Jan;41(1):45-60. doi: 10.1016/j.ejca.2004.10.016.Cao L, Tong H, Xu G, et al. Systemic lupus erythematous and malignancy risk: a meta-analysis. PLoS One. 2015 Apr 17;10(4): e0122964. doi: 10.1371/journal.pone.0122964. eCollection 2015.Cao L, Tong H, Xu G, et al. Systemic lupus erythematous and malignancy risk: a meta-analysis. PLoS One. 2015 Apr 17;10(4): e0122964. doi: 10.1371/journal.pone.0122964. eCollection 2015.Singh AG, Crowson CS, Singh S, et al. Cancer risk in cutaneous lupus erythematosus: a population-based cohort study. Rheumatology (Oxford). 2016 Nov;55(11):2009-13. doi: 10.1093/rheumatology/kew291. Epub 2016 Aug 12.Singh AG, Crowson CS, Singh S, et al. Cancer risk in cutaneous lupus erythematosus: a population-based cohort study. Rheumatology (Oxford). 2016 Nov;55(11):2009-13. doi: 10.1093/rheumatology/kew291. Epub 2016 Aug 12.Chow MT, Möller A, Smyth MJ. Inflammation and immune surveillance in cancer. Semin Cancer Biol. 2012 Feb;22(1): 23-32. doi: 10.1016/j.semcancer.2011.12.004. Epub 2011 Dec 24.Chow MT, Möller A, Smyth MJ. Inflammation and immune surveillance in cancer. Semin Cancer Biol. 2012 Feb;22(1): 23-32. doi: 10.1016/j.semcancer.2011.12.004. Epub 2011 Dec 24.Yadav S, Singh S, Harmsen WS, et al. Effect of Medications on Risk of Cancer in Patients With Inflammatory Bowel Diseases: A Population-Based Cohort Study from Olmsted County, Minnesota. Mayo Clin Proc. 2015 Jun;90(6):738-46. doi: 10.1016/j.mayocp.2015.03.024. Epub 2015 May 9.Yadav S, Singh S, Harmsen WS, et al. Effect of Medications on Risk of Cancer in Patients With Inflammatory Bowel Diseases: A Population-Based Cohort Study from Olmsted County, Minnesota. Mayo Clin Proc. 2015 Jun;90(6):738-46. doi: 10.1016/j.mayocp.2015.03.024. Epub 2015 May 9.Trousseau A. Phlegmasia alba dolens Clinique Medical de L'HotelDieu de Paris. Vol. 3. London: The New Sydenham Society; 1865. 94 p.Trousseau A. Phlegmasia alba dolens Clinique Medical de L'HotelDieu de Paris. Vol. 3. London: The New Sydenham Society; 1865. 94 p.Lee AY, Levine MN. Venous thromboembolism and cancer: risks and outcomes. Circulation. 2003 Jun 17;107(23 Suppl 1): I17-21. doi: 10.1161/01.CIR.0000078466.72504.AC.Lee AY, Levine MN. Venous thromboembolism and cancer: risks and outcomes. Circulation. 2003 Jun 17;107(23 Suppl 1): I17-21. doi: 10.1161/01.CIR.0000078466.72504.AC.Wuepper KD, Tuffanelli DL. False-positive reaction to VRDL test with prozone phenomena. Association with lymphosarcoma. JAMA. 1966 Mar 7;195(10):868-9. doi: 10.1001/jama.1966.03100100120044.Wuepper KD, Tuffanelli DL. False-positive reaction to VRDL test with prozone phenomena. Association with lymphosarcoma. JAMA. 1966 Mar 7;195(10):868-9. doi: 10.1001/jama.1966.03100100120044.Schleider MA, Nachman RL, Jaffe EA, Coleman M. A clinical study of the lupus anticoagulant. Blood. 1976 Oct;48(4): 499-509.Schleider MA, Nachman RL, Jaffe EA, Coleman M. A clinical study of the lupus anticoagulant. Blood. 1976 Oct;48(4): 499-509.Falcon CR, Hoffer AM, Carreras LO. Antiphosphatidylinositol antibodies as markers of the antiphospholipid syndrome. Thromb Haemost. 1990 Apr 12;63(2):321-2.Falcon CR, Hoffer AM, Carreras LO. Antiphosphatidylinositol antibodies as markers of the antiphospholipid syndrome. Thromb Haemost. 1990 Apr 12;63(2):321-2.Stern JJ, Ng RH, Triplett DA, McIntyre JA. Incidence of antiphospholipid antibodies in patients with monoclonal gammopathy of undetermined significance. Am J Clin Pathol. 1994 Apr;101(4):471-4. doi: 10.1093/ajcp/101.4.471.Stern JJ, Ng RH, Triplett DA, McIntyre JA. Incidence of antiphospholipid antibodies in patients with monoclonal gammopathy of undetermined significance. Am J Clin Pathol. 1994 Apr;101(4):471-4. doi: 10.1093/ajcp/101.4.471.Zuckerman E, Toubi E, Golan TD, et al. Increased thromboembolic incidence in anticardiolipin-positive patients with malignancy. Br J Cancer. 1995 Aug; 72(2): 447-51. doi: 10.1038/bjc.1995.353.Zuckerman E, Toubi E, Golan TD, et al. Increased thromboembolic incidence in anticardiolipin-positive patients with malignancy. Br J Cancer. 1995 Aug; 72(2): 447-51. doi: 10.1038/bjc.1995.353.Gomez-Puerta JA, Cervera R, Espinosa G, et al. Antiphospholipid antibodies associated with malignancies: clinical and pathological characteristics of 120 patients. Semin Arthritis Rheum. 2006 Apr;35(5):322-32. doi: 10.1016/j.semarthrit.2005.07.003.Gomez-Puerta JA, Cervera R, Espinosa G, et al. Antiphospholipid antibodies associated with malignancies: clinical and pathological characteristics of 120 patients. Semin Arthritis Rheum. 2006 Apr;35(5):322-32. doi: 10.1016/j.semarthrit.2005.07.003.Choi MY, Flood K, Bernatsky S, Ramsey-Goldman R, Clarke AE. A review on SLE and malignancy. Best Pract Res Clin Rheumatol. 2017 Jun;31(3):373-396. doi: 10.1016/j.berh.2017.09.013.Choi MY, Flood K, Bernatsky S, Ramsey-Goldman R, Clarke AE. A review on SLE and malignancy. Best Pract Res Clin Rheumatol. 2017 Jun;31(3):373-396. doi: 10.1016/j.berh.2017.09.013.Song L, Wang Y, Zhang J, et al. The risks of cancer development in systemic lupus erythematosus (SLE) patients: a systematic review and meta-analysis. Arthritis Res Ther. 2018 Dec 6;20(1):270. doi: 10.1186/s13075-018-1760-3.Song L, Wang Y, Zhang J, et al. The risks of cancer development in systemic lupus erythematosus (SLE) patients: a systematic review and meta-analysis. Arthritis Res Ther. 2018 Dec 6;20(1):270. doi: 10.1186/s13075-018-1760-3.Jacobs JVG, Bijlsma JVG. Glucocorticoid therapy. In Firestein GS, Budd RC, Gabriel SE, editors. Kelley and Firestein's Textbook of Rheumatology. 10th ed. Philadelphia: Elsevier; 2017. P. 932-57.Jacobs JVG, Bijlsma JVG. Glucocorticoid therapy. In Firestein GS, Budd RC, Gabriel SE, editors. Kelley and Firestein's Textbook of Rheumatology. 10th ed. Philadelphia: Elsevier; 2017. P. 932-57.Яблонский ПК, редактор. Фтизиатрия. Национальные клинические рекомендации. Москва: ГЭОТАР-Медиа; 2016. 240 с.Yablonskii PK, editor. Ftiziatriya. Natsional'nye klinicheskie rekomendatsii [Phthisiology. National clinical guidelines]. Moscow: GEOTAR-Media; 2016. 240 p.Ghosh K, Patwardhan M, Pradhan V. Mycobacterium tuberculosis infection precipitates SLE in patients from endemic areas. Rheumatol Int. 2009 Jul;29(9):1047-50. doi: 10.1007/s00296-009-0903-x. Epub 2009 Apr 10.Ghosh K, Patwardhan M, Pradhan V. Mycobacterium tuberculosis infection precipitates SLE in patients from endemic areas. Rheumatol Int. 2009 Jul;29(9):1047-50. doi: 10.1007/s00296-009-0903-x. Epub 2009 Apr 10.Hernandez-Cruz B, Sifuentes-Osornio J, Ponce-de-Leon Rosales S, et al. Mycobacterium tuberculosis infection in patients with systemic rheumatic diseases. A case-series. Clin Exp Rheumatol. 1999 May-Jun;17(3): 289-96.Hernandez-Cruz B, Sifuentes-Osornio J, Ponce-de-Leon Rosales S, et al. Mycobacterium tuberculosis infection in patients with systemic rheumatic diseases. A case-series. Clin Exp Rheumatol. 1999 May-Jun;17(3): 289-96.Park DW, Chung SJ, Yeo Y, et al. Therapeutic issues with, and long-term outcomes of, pulmonary mycobacterial tuberculosis treatment in patients with autoimmune rheumatic diseases. J Thorac Dis. 2019 Nov; 11(11):4573-82. doi: 10.21037/jtd.2019.10.74.Park DW, Chung SJ, Yeo Y, et al. Therapeutic issues with, and long-term outcomes of, pulmonary mycobacterial tuberculosis treatment in patients with autoimmune rheumatic diseases. J Thorac Dis. 2019 Nov; 11(11):4573-82. doi: 10.21037/jtd.2019.10.74.Gatto M, Saccon F, Zen M, et al. Success and failure of biological treatment in systemic lupus erythematosus: A critical analysis. J Autoimmun. 2016 Nov;74:94-105. doi: 10.1016/j.jaut.2016.06.014. Epub 2016 Jun 30.Gatto M, Saccon F, Zen M, et al. Success and failure of biological treatment in systemic lupus erythematosus: A critical analysis. J Autoimmun. 2016 Nov;74:94-105. doi: 10.1016/j.jaut.2016.06.014. Epub 2016 Jun 30.Stohl W, Schwarting A, Okada M, et al. Efficacy and Safety of Subcutaneous Belimumab in Systemic Lupus Erythematosus: A Fifty-Two-Week Randomized, Double-Blind, Placebo-Controlled Study. Arthritis Rheumatol. 2017 May;69(5):1016-27. doi: 10.1002/art.40049. Epub 2017 Apr 7.Stohl W, Schwarting A, Okada M, et al. Efficacy and Safety of Subcutaneous Belimumab in Systemic Lupus Erythematosus: A Fifty-Two-Week Randomized, Double-Blind, Placebo-Controlled Study. Arthritis Rheumatol. 2017 May;69(5):1016-27. doi: 10.1002/art.40049. Epub 2017 Apr 7.Diaz-Lagares C, Perez-Alvarez R, Garcia-Hernandez FJ, et al. Rates of, and risk factors for, severe infections in patients with systemic autoimmune diseases receiving biological agents off-label. Arthritis Res Ther. 2011 Jul 11;13(4):R112. doi: 10.1186/ar3397.Diaz-Lagares C, Perez-Alvarez R, Garcia-Hernandez FJ, et al. Rates of, and risk factors for, severe infections in patients with systemic autoimmune diseases receiving biological agents off-label. Arthritis Res Ther. 2011 Jul 11;13(4):R112. doi: 10.1186/ar3397.

The authors declare that there are no conflicts of interest present.